Developing a new nanoparticle drug to treat pancreatic cancer
Translational Development of a Targeted and Stroma-penetrating Nanoparticle Drug for Pancreatic Cancer Therapy
This study is testing a new tiny drug delivery system that helps a powerful medicine reach pancreatic tumors more effectively, with the hope of improving treatment for patients battling pancreatic cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Migra-Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Atlanta, UNITED STATES) |
| Project ID | NIH-10705200 on NIH RePORTER |
What this research studies
This research focuses on creating a specialized nanoparticle drug designed to penetrate the dense stroma of pancreatic tumors, which often hinders effective treatment. The nanoparticle carries a potent drug, SN38, which has shown promise in overcoming drug resistance in pancreatic cancer cells. By enhancing drug delivery directly to the tumor, this approach aims to improve therapeutic outcomes for patients. The research involves preclinical studies using patient-derived models to test the effectiveness of this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer, particularly those who have experienced drug resistance to current therapies.
Not a fit: Patients with non-cancerous conditions or those with pancreatic cancer that is not drug-resistant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in using nanoparticles for drug delivery in cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Atlanta, UNITED STATES
- Migra-Therapeutics, LLC — Atlanta, United States (Active)
Researchers
- Principal investigator: Zhu, Lei — Migra-Therapeutics, LLC
- Study coordinator: Zhu, Lei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.